

# FOUR-YEAR EFFECTIVENESS OF COVID-19 VACCINES AGAINST SEVERE DISEASE AND ASYMPTOMATIC INFECTION: THE COVIDVAC@SPAIN STUDY

**First published:** 22/09/2021

**Last updated:** 23/04/2024

Study

Planned

## Administrative details

### EU PAS number

EUPAS43186

---

### Study ID

43187

---

### DARWIN EU® study

No

---

### Study countries

 Spain

---

### Study description

## Study status

Planned

## Research institutions and networks

### Institutions

#### Hospital La Paz

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

#### School of Medicine

#### Clinical Pharmacology Department, Hospital La Paz, School of Medicine

 Spain

**First published:** 24/10/2022

**Last updated:** 19/12/2025

Institution

Educational Institution

Hospital/Clinic/Other health care facility

ENCePP partner

# Networks

SCReN

## Contact details

### Study institution contact

Antonio J Carcas [antonio.carcas@uam.es](mailto:antonio.carcas@uam.es)

Study contact

[antonio.carcas@uam.es](mailto:antonio.carcas@uam.es)

### Primary lead investigator

Antonio J Carcas

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 30/09/2021

---

### Study start date

Planned: 04/10/2021

---

### Date of final study report

Planned: 30/09/2025

## Sources of funding

- Other

## More details on funding

Instituto de Salud Carlos III

## Regulatory

### **Was the study required by a regulatory body?**

Yes

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

#### **Study type:**

Non-interventional study

---

#### **Scope of the study:**

Effectiveness study (incl. comparative)

#### **Main study objective:**

Estimate: 1) vaccine effectiveness (VE) of approved COVID vaccines in preventing asymptomatic infection, 2) the viral replication difference in

vaccinated vs non-vaccinated subjects, 3) the VE of approved COVID vaccines in preventing severe outcomes in persons who require hospitalization, 4) if the VE from objective #3 varies according to SARS-CoV-2 variants or strains carrying specific mutation

## Study Design

### **Non-interventional study design**

Other

---

### **Non-interventional study design, other**

Retrospective observational epidemiological study

## Study drug and medical condition

### **Medical condition to be studied**

COVID-19 immunisation

## Population studied

### **Age groups**

- Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)
- 

### **Estimated number of subjects**

## Study design details

### Outcomes

Substudy A: SARS-CoV-2 PCR positive/negative results Substudy B: • Maximum level of oxygen support required • ICU admission (and duration) • Mechanical ventilation (and duration) • Pulmonary embolism • Death or discharge hospitalization • Total duration of hospital stay, Interaction between vaccination. Variant-specific VE

---

### Data analysis plan

For main objective #1, multivariate logistic regression will be used. For main objective #2 a sub-analysis of positive cases will be carried out and mean Ct values will be compared between vaccinated and non-vaccinated groups using generalized linear models. For main objectives #3 and #4, longitudinal data will be analysed using either multivariate Poisson models or survival analysis and Cox regression. For secondary objectives #1, #2 and #3, interaction between vaccination and independent variables will be tested, and stratified estimations in groups defined by vaccination schedule, age, sex, previous SARS-CoV-2 infection and comorbidities will be performed. For secondary objective #4 all project data will be pooled and an interaction between study period (selection-round) and vaccination status will be tested to analyse statistically significant variation in VE. Stata v15.0.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data sources (types)

Other

---

### Data sources (types), other

Medical records: retrospective study

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

### Check conformance

Unknown

---

### Check completeness

Unknown

---

### Check stability

Unknown

---

**Check logical consistency**

Unknown

**Data characterisation**

**Data characterisation conducted**

No